FDA approves Lumakras the first and only targeted treatment for KRAS G12C-mutated locally advanced or metastatic NSCLC – Amgen
Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351
Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot accept responsibility for the authenticity of the content matter.
Copyright: The copyright of the material on this site rests with the author unless otherwise indicated. It is a breach of copyright to use any material from this site without prior written consent.